首页> 外文期刊>Oncology reports >VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN
【24h】

VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN

机译:VEGFR3抑制在肿瘤相关巨噬细胞微环境中的肺腺癌A549细胞通过P53和PTEN的上调

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In lung adenocarcinoma, loss of p53 and PTEN in tumors are associated with decreased response to chemotherapy and decreased survival. A means to pharmacologically upregulate p53 and PTEN protein expression could improve the prognosis of patients with p53- and PTEN-deficient tumors. In the present study we revealed that vascular endothelial growth factor receptor 3 (VEGFR3) inhibition in lung adenocarcinoma cells was associated with improved expression levels of both p53 and PTEN in the tumor-associated macrophage (TAM) micro-environment. Inhibition of VEGFR3 in lung adenocarcinoma cells was associated with growth arrest and decreased migration and invasion. The upregulation of p53 and PTEN protein expression after VEGFR3 inhibition decreased chemotherapy resistance and improved chemosensitivity in co-cultured A549 cells in which p53 and PTEN expression were decreased. Finally, we demonstrated that TAMs promoted the expression of VEGF-C and its receptor VEGFR3. Western blot analysis revealed the co-cultured A549 cells with TAMs are a primary source of VEGF-C and VEGFR3 in the tumor micro-environment. Our studies revealed that VEGFR3 inhibition may be a pharmacological means to upregulate p53 and PTEN protein expression and improve the outcome of patients with p53- and PTEN-deficient tumors.
机译:在肺腺癌中,肿瘤中P53和PTEN的损失与对化疗的反应减少和存活率下降有关。药理学上调P53和PTEN蛋白表达的方法可以改善P53-和PTEN缺乏肿瘤患者的预后。在本研究中,我们揭示了血管内皮生长因子受体3(VEGFR3)在肺腺癌细胞中抑制与肿瘤相关的巨噬细胞(TAM)微环境中P53和PTEN的改善表达水平相关。 VEGFR3在肺腺癌细胞中的抑制与生长骤停和迁移和侵袭下降有关。 VEGFR3抑制后P53和PTEN蛋白表达的上调降低了化疗抗性,改善了共培养A549细胞中的化学敏感性,其中P53和PTEN表达降低。最后,我们证明了TAMS促进了VEGF-C及其受体VEGFR3的表达。 Western印迹分析显示,具有TAM的共培养的A549细胞是肿瘤微环境中VEGF-C和VEGFR3的主要来源。我们的研究表明,VEGFR3抑制可以是药理学手段,用于上调P53和PTEN蛋白表达,并改善P53和PTEN缺乏肿瘤患者的结果。

著录项

  • 来源
    《Oncology reports》 |2017年第5期|共13页
  • 作者单位

    Chongqing Med Univ Dept Lab Med Key Lab Lab Med Diagnost MOE Chongqing 400016 Peoples R China;

    Chongqing Med Univ Dept Lab Med Key Lab Lab Med Diagnost MOE Chongqing 400016 Peoples R China;

    Chongqing Med Univ Dept Lab Med Key Lab Lab Med Diagnost MOE Chongqing 400016 Peoples R China;

    Chongqing Med Univ Dept Lab Med Key Lab Lab Med Diagnost MOE Chongqing 400016 Peoples R China;

    Xinxiang Med Univ Dept Clin Med Xinxiang 453003 Henan Peoples R China;

    Chongqing Med Univ Dept Lab Med Key Lab Lab Med Diagnost MOE Chongqing 400016 Peoples R China;

    Chongqing Med Univ Dept Lab Med Key Lab Lab Med Diagnost MOE Chongqing 400016 Peoples R China;

    Chongqing Med Univ Dept Lab Med Key Lab Lab Med Diagnost MOE Chongqing 400016 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    tumor-associated macrophage; vascular endothelial growth factor receptor 3; A549 cells; p53; PTEN; chemosensitivity;

    机译:肿瘤相关的巨噬细胞;血管内皮生长因子受体3;A549细胞;P53;PTEN;化学敏感;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号